Most of the exciting work being done right now in cancer immunotherapy is centred on highly targeted approaches that aim to activate only the most necessary immune responses to eliminate a
Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical Oncology (ESMO) Congress in Madrid 20th-24th October, which was back at full capac
Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced las
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.